EP-2104R is a molecularly targeted
MRI contrast agent for high
resolution blood clot imaging within half an hour of injection. This
gadolinium based small peptide has high affinity and specificity for human fibrin.
The thrombus agent is a new class of
contrast medium for the diagnostic of, e.g. deep venous thrombosis, carotid artery blood clots, coronary artery blood clots and pulmonary embolism. Fibrin is an excellent target for a
molecular imaging contrast agent, since it is present in arterial and venous clots at high concentrations (20-100 μM), and is a target for fibrinolytic therapy.
Due to financial problems, the developer
EPIX Pharmaceuticals, Inc. had to shut down all operations. As a consequence, the development of EP-2104R is discontinued.